Winklevoss twins launch Cypherpunk Technologies with $50M Zcash bet on financial privacy
Key Points
- The Winklevoss twins invested $52 million in Cypherpunk Technologies' PIPE round, taking the vast majority of equity themselves to ensure long-term holders dominate the shareholder base rather than traders.
- Cypherpunk Technologies, a rebranded public company trading under ticker CYPH, is accumulating Zcash as its core treasury strategy, having purchased 203,775 ZEC at an average price of $245 per token.
- The twins are positioning themselves as conviction holders in financial privacy infrastructure, mirroring their strategic preference for ownership concentration over capital diversification.
Summary
Read full transcript →The Winklevoss twins anchored the Cypherpunk Technologies PIPE financing with a $52 million check, deliberately taking the vast majority of the equity themselves rather than filling the round with outside capital. The strategic logic is straightforward: they want the shareholder base dominated by long-term holders, not traders rotating in and out. That concentration of ownership mirrors a conviction bet on Zcash and financial privacy infrastructure, with the twins positioning as holders rather than flippers.
The segment transitions to Max Hodak, co-founder of Science and a co-founder of Neuralink, where he spent four and a half years before departing in spring 2021. Science now employs roughly 180 people and is developing what Hodak describes as the first clinically effective retinal prosthesis.
“We launched Cypherpunk, a Zcash DAT yesterday. It trades under Cyph. The mission of the company is privacy and self-sovereignty. Starting by accumulating Zcash. We put a $52 million check in. The vast majority of equity will not be trading out of the shares — we're long-term holders.”
Science's Prima Retinal Chip
The company's lead program, Prima, is a subretinal implant that works in tandem with laser projection glasses worn by the patient. The device targets age-related macular degeneration, a condition that leaves patients profoundly blind in their central visual field while retaining limited peripheral vision.
A major clinical trial completed last summer and results were published in the New England Journal of Medicine. The headline outcome is material: patients who entered the trial unable to read any line of an eye chart progressed to reading the full chart. Hodak frames restoring vision to the blind as a problem humans have pursued for thousands of years, and positions the New England Journal publication, alongside a Time magazine cover the week of the segment, as validation that the science is translating into real clinical results.
Every deal, every interview. 5 minutes.
TBPN Digest delivers summaries of the latest fundraises, interviews and tech news from TBPN, every weekday.